Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Danaher Corporation (DHR) — XLV Health Care · S&P 500 Profile |丹納赫介紹

health-careS&P500xlvxlv-top-25
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Danaher Corporation (DHR) — Business, History & S&P 500 Profile | 丹納赫

Danaher Corporation company profile · business segments · history · financial snapshot · S&P 500 rank #75 · 丹納赫公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Oct 29, 2026 (ET) close
Financials: FY2024
MARKET CAP
$166.59B
Oct 29, 2026 close
S&P 500 WEIGHT
0.24%
Rank #75 · Oct 29, 2026
SECTOR RANK
#11
Health Care · Oct 29, 2026
S&P 500 RANK
#75
0.24% · Oct 29, 2026

SNAPSHOT

TickerDHR
CompanyDanaher Corporation
GICS sector / industryHealth Care (XLV) / Life Sciences Tools & Services
S&P 500 rank (by weight)#75 · 0.24% (Oct 29, 2026)
Sector rank#11 in Health Care (Oct 29, 2026)
HeadquartersWashington, D.C.
Founded1984
CEORainer M. Blair
EmployeesApproximately 63,000 (Dec 31, 2024)
Market cap$166.59B (Oct 30, 2026)
Share price$232.23 (Oct 30, 2026 close)
SEC filingsEDGAR — CIK 0000313616

WHAT IT DOES

Danaher sells life-sciences tools, diagnostics and bioprocessing products used to discover, develop and manufacture drugs.

Its biotechnology segment, including Cytiva, supplies the filters, resins and systems biomanufacturers need.

Diagnostics, including Beckman Coulter and Cepheid, serves hospitals and laboratories.

BUSINESS SEGMENTS

BiotechnologyBioprocessing products for drug manufacturing, including Cytiva. FY2024 revenue $6,759M; operating income $1,685M.
Life SciencesInstruments and consumables for research laboratories. FY2024 revenue $7,329M; operating income $879M.
DiagnosticsClinical diagnostics including Beckman Coulter and Cepheid. FY2024 revenue $9,787M; operating income $2,625M.

HISTORY

YearMilestone
1984Steven and Mitchell Rales found Danaher.
2016Danaher spins off its industrial businesses as Fortive.
2020Danaher acquires Cytiva.
2023Danaher spins off its environmental and applied solutions businesses as Veralto.

COMPETITIVE POSITION

  • Bioprocessing equipment and consumables
  • Genomic and proteomic instruments
  • Clinical laboratory diagnostics
  • Microbiology testing systems

FINANCIAL SNAPSHOT

Total revenue$24.57B (FY2025 sales)
Operating income$4.69B (FY2025 operating profit)
Net income$3.61B (FY2025 net earnings)
Diluted EPS$5.05 (FY2025 diluted EPS from continuing operations)
Source: Danaher Corporation Form 10-K / 2025 annual report (sales $24.57B; operating profit $4.69B; net earnings $3.61B; diluted EPS $5.05 from continuing operations).

KEY RISKS

  • Bioprocessing demand follows biotech funding cycles, which can contract sharply.
  • Customer destocking after pandemic-era inventory build can depress orders.
  • Acquired businesses must keep growing to justify Danaher's acquisition prices.
  • Diagnostics reimbursement and regulation can shift revenue.
  • Currency moves affect a business with most sales outside the United States.

WHY IT MATTERS FOR THE S&P 500

Danaher is the picks-and-shovels play on drug development: it sells the tools every biomanufacturer needs, with the Danaher Business System driving margins. The risk is the biotech funding cycle, which swings demand for its highest-margin bioprocessing products.

SOURCES & METHODOLOGY

Financials, segments, headquartersDanaher Corporation Form 10-K / 2024 annual report (sales $23.88B; operating profit $4.86B; net earnings $3.90B; diluted EPS $5.29 from continuing operations).
Index weight & ranksSlickcharts S&P 500 weights, Oct 29, 2026 close, fetched Oct 30, 2026
Market cap$166.59B (Oct 30, 2026)
LogoSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics.
ChartSPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

DHR

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

股票代號DHR
公司丹納赫公司
GICS 板塊/行業健康護理(XLV)/生命科學工具與服務
標普500排名(按權重)#75 · 0.24%(Oct 29, 2026)
板塊內排名健康護理 #11(Oct 29, 2026)
總部華盛頓特區
成立1984 年
執行長雷納·M·布萊爾
員工約 63,000 人(2024 年 12 月 31 日)
市值$166.59B(Oct 30, 2026)
股價$232.23(Oct 30, 2026 收盤)
SEC 申報EDGAR — CIK 0000313616

業務概覽

丹納赫銷售用於發現、開發與製造藥物的生命科學工具、診斷與生物工藝產品。

其生物技術分部(包括 Cytiva)供應生物製造商所需的過濾器、樹脂與系統。

診斷業務(包括 Beckman Coulter 與 Cepheid)服務醫院與實驗室。

業務板塊

生物技術藥物製造的生物工藝產品,包括 Cytiva。 2024 財年收入 67.59 億美元;營業利潤 16.85 億美元。
生命科學研究實驗室的儀器與耗材。 2024 財年收入 73.29 億美元;營業利潤 8.79 億美元。
診斷臨床診斷,包括 Beckman Coulter 與 Cepheid。 2024 財年收入 97.87 億美元;營業利潤 26.25 億美元。

歷史沿革

年份里程碑
1984 年史蒂文與米切爾·雷爾斯創立丹納赫。
2016 年丹納赫分拆工業業務為 Fortive。
2020 年丹納赫收購 Cytiva。
2023 年丹納赫分拆環境與應用解決方案業務為 Veralto。

競爭地位

  • 生物工藝設備與耗材
  • 基因組與蛋白質組儀器
  • 臨床實驗室診斷
  • 微生物檢測系統

財務快照

總收入$24.57B(FY2025 銷售額)
營業利潤$4.69B(FY2025 營業利潤)
淨利潤$3.61B(FY2025 淨利潤)
稀釋 EPS$5.05(FY2025 持續經營攤薄每股收益)
來源:丹納赫 2025 年報/Form 10-K(銷售額 245.7 億美元;營業利潤 46.9 億美元;淨利潤 36.1 億美元;持續經營攤薄每股收益 5.05 美元)。

主要風險

  • 生物工藝需求跟隨生物科技融資週期,可能急劇收縮。
  • 疫情時期庫存累積後的客戶去庫存可能壓低訂單。
  • 被收購業務必須持續增長,才能證明丹納赫的收購價格合理。
  • 診斷報銷與監管可能改變收入。
  • 匯率波動影響以美國以外銷售為主的業務。

對標普500的重要性

丹納赫是藥物開發的「賣鏟人」:它銷售每家生物製造商都需要的工具,並以丹納赫業務系統推動利潤。風險在於生物科技融資週期,它會波動最高利潤生物工藝產品的需求。

來源與方法

財務、板塊、總部丹納赫 2024 年報/Form 10-K(銷售額 238.8 億美元;營業利潤 48.6 億美元;淨利潤 39.0 億美元;持續經營攤薄每股收益 5.29 美元)。
指數權重與排名Slickcharts S&P 500 權重,Oct 29, 2026 收盤,Oct 30, 2026 抓取
市值$166.59B(Oct 30, 2026)
LogoSPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。
股價圖SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

DHR

來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · DHR
Data as of Oct 29, 2026 · Financials FY2024 (10-K) · Market data Oct 2026
Previous · Seagate Technology Holdings plc (STX) — XLK Information Technology · S&P 500 Profile |希捷科技介紹Next · Welltower Inc. (WELL) — XLRE Real Estate · S&P 500 Profile |Welltower介紹

Entered 2026-10-30 05:26 · updated 2026-11-14 23:18 · rev 9